Modern oncology depends on digital systems that automate medication management, standardize chemotherapy workflows, and provide a single source of truth for multidisciplinary care. As treatment regimens grow more complex, hospitals need platforms that are reliable, consistent, and built specifically for oncology. Today, specialty-focused software has become central to cancer centers, integrating clinical processes with administrative, pharmacy, and research functions.
Among the platforms shaping this transition is Altai Oncology Suite, developed by Altai Inc. Founded in 2013 and headquartered in Sheridan, Wyoming, the company designs health information technology exclusively for hematology and oncology practices. Its flagship Windows-based platform supports cancer centers and infusion clinics of all sizes, offering modules for chemotherapy order entry, scheduling, dose calculations, pharmacy operations, cancer registry functions, reporting, and billing. The system is CE-marked as a Class IIb medical device and supported by development teams in both the United States and Turkey.
At the heart of the Altai Oncology Suite are tools built to handle the full scope of chemotherapy planning and administration. Clinicians can select standardized protocols, adjust doses based on clinical conditions, and generate complete treatment plans within the computerized order entry system. Automated dose calculators incorporate body surface area, renal function, and laboratory parameters, reducing manual calculations and minimizing the potential for human error. These features consolidate the information oncologists, pharmacists, and nurses need throughout the treatment cycle.
Beyond order entry, the platform includes comprehensive operational tools. The scheduling module manages infusion chairs, appointments, and resource allocation. Pharmacy features track inventory, preparation steps, and dispensing processes. The built-in cancer registry module supports documentation of staging, toxicities, and outcomes, creating a structured environment for quality monitoring and research activities. Together, these components form an integrated system that coordinates care across departments.
Customizability is one of the platform’s strongest advantages. Clinics can tailor workflows, infusion rates, drug lists, templates, and documentation fields to reflect their operational models and regulatory needs. Institutions can also build their own protocols within the system—useful for centers participating in clinical trials or implementing multidisciplinary treatment pathways. This flexibility helps practices adopt the software without disrupting established routines.
The platform emphasizes safety through automated checks for dose limits, drug interactions, allergies, and lab-based dose modifications. These safeguards support accurate ordering and reduce transcription-related risks. Operational efficiency is enhanced by quick-note templates, inventory tools, and streamlined scheduling, allowing staff to spend more time with patients and less time navigating multiple systems.
Interoperability is another central feature. Altai Oncology Suite integrates with EHR systems, laboratories, and dispensing units via HL7 channels or custom APIs. This connectivity reduces duplicate documentation, improves data accuracy, and ensures reliable communication between clinical and administrative systems. Unified access to demographics, labs, treatment histories, and billing information strengthens continuity of care and supports compliance and reporting requirements.
Although software cannot replace clinical judgment, it can significantly reduce the administrative burden surrounding treatment planning and documentation. By standardizing protocols, automating dose calculations, and generating structured notes, Altai Oncology Suite enables clinicians to shift time back toward patient interaction, verification, and monitoring.
The suite is complemented by Altai’s curated protocol library—a collection of more than 1,000 oncology and hematology protocols maintained since 2015. Available across both desktop and mobile applications, the library provides clinicians with up-to-date treatment pathways and administration criteria without the need to consult multiple resources.
As cancer centers continue adopting digital infrastructure, platforms like Altai Oncology Suite are helping reshape how oncology services are organized and delivered. The combination of chemotherapy management, registry tools, inventory control, and system integration reflects a broader trend toward specialty-specific health information systems that prioritize precision, safety, and operational efficiency.
Looking ahead, oncology software will increasingly depend on advancements in interoperability, data analytics, and clinical decision support. Positioned at the intersection of cancer care and technology, Altai Oncology is well-prepared to support this evolution and strengthen digital workflows across treatment centers worldwide.
Disclaimer: The content in this article is based on information about the Altai Oncology Suite as provided by Altai Inc. The platform’s features, including chemotherapy order entry, dose calculations, and protocol libraries, are designed to support oncology workflows. Claims regarding the software’s ability to improve safety, reduce errors, or enhance operational efficiency are based on vendor descriptions and should be considered as such. These claims have not been independently verified by clinical studies or regulatory bodies. While the Altai Oncology Suite is CE‑marked, it is important to note that the software’s approval status may differ across regions, and it is not FDA‑approved as a medical device in the U.S. Always consult relevant healthcare professionals and conduct thorough evaluations before making decisions related to medical technology.
